Literature DB >> 26885351

Elevated Plasma Homocysteine Concentration in Opium-Addicted Individuals.

Mohammad Masoomi1, Nahid Azdaki2, Beydolah Shahouzehi3.   

Abstract

BACKGROUND: Although the triggering role of both opium use and elevated plasma homocysteine level for progressing atherosclerosis and, therefore, appearing coronary heart disease has been clearly determined, no study are available with respect to the relation between these to risk profiles. In the present study and for the first time, we hypothesized that the opium addiction can be potentially correlated with elevated homocysteine concentration.
METHODS: 217 persons (103 opium-addicted and 114 non-addicted) were randomly selected from the Kerman Coronary Artery Disease Risk Study (KERCADRS), Iran, as a population-based, epidemiological prospective study. In all participants, an enzyme immunoassay kit was used to measure homocysteine in serum samples.
FINDINGS: The serum level of homocysteine was significantly higher in the opium-addicted ones compared to non-addicted individuals (11.49 ± 7.45 vs. 8.02 ± 3.87 μmol/l) (P < 0.001). In this regard, 21.3% of the opium users and only 3.2% of the non-users had homocysteine concentration > 15 μmol/l (P < 0.001). On the other hand, individuals addicted to opiates exhibited significantly elevated odds of having homocysteine level higher than 15 [odds ratio (OR) = 8.244, 95% confidence interval (CI) = 3.117-21.806]. Multivariable linear regression model showed that the opium addiction could strongly predict elevated homocysteine level in the study individuals [beta = 3.524, standard error (SE) = 0.852] (P < 0.001).
CONCLUSION: Opium consumption can be strongly accompanied with the elevation of plasma homocysteine concentration, and thus opium addiction can exhibit elevated odds of having hyperhomocysteinemia.

Entities:  

Keywords:  Cardiovascular disease; Homocysteine; Opium addiction

Year:  2015        PMID: 26885351      PMCID: PMC4741235     

Source DB:  PubMed          Journal:  Addict Health        ISSN: 2008-4633


Introduction

The majority of prospective studies could show that elevated plasma total homocysteine level was an important risk factor for developing coronary atherosclerosis and pathological changes in cerebrovascular and peripheral vascular systems.1-5 Recent investigations have produced some probable mechanisms responsible for the appearance of atherosclerotic lesions following elevation of this biomarker including vascular endothelial defects, increased uptake of modified low density lipoprotein, stimulating proliferation of smooth muscles, and antithrombotic abnormalities.6 High levels of homocysteine are believed to promote the formation of oxidation products such as homocysteine and homocysteine disulfides, as well as homocysteine thiolactone, which can damage endothelial cells by excessive sulfation of collagen.7-9 Furthermore, it has been suggested that the defects in intracellular homocysteine metabolism frequently an inadequate intake of folate or vitamins B-6 or B-12 as cofactors or substrates for the enzymes involved in homocysteine metabolism can result in elevated plasma homocysteine concentrations.10,11 These metabolic defects are usually occurred following abnormalities in either genetic or nutritional backgrounds.12 Besides, the life-threatening events associated with the use of opium or its purified agents have captured the attention of clinical researchers. It has been demonstrated that serum levels of some biochemical risk factors for coronary artery disease (CAD) such as lipoprotein (a) and C-reactive protein were significantly higher in opium-addicted patients and these factors were major determinants of risk factor for premature atherosclerosis.13 Furthermore, in some recent clinical studies, role of opium addiction on progressing coronary atherosclerosis and its related poor outcome has been identified.14-16 Although the triggering role of both opium use and elevated plasma homocysteine level for progressing atherosclerosis and, therefore, appearing coronary heart disease has been clearly determined, no study are available with respect to the relation between these to risk profiles. In the present study and for the first time, we hypothesized that the opium addiction can be potentially correlated with elevated homocysteine concentration and thus can trigger its serum level elevation.

Methods

The Kerman Coronary Artery Disease Risk Study (KERCADRS), Iran, is a population-based, epidemiological study among 6000 individuals aged 15-75 years and residence in Kerman city addressing the information of six risk factors of coronary artery disease (CAD) including serum lipids, physical activity, alcohol and drugs addiction, mental disorders like stress and depression, hypertension, and diet regimen.17 These individuals were given the study questionnaires by a general practitioner about their medical history including CAD risk factors: current smoking history (patients regularly smoke a tobacco product/products 1 or more times per day or have smoked in the 30 days prior to admission),18 hypercholesterolemia (total cholesterol ≥ 5.0 mmol/l, high-density lipoprotein cholesterol ≥ 1.0 mmol/l in men, or ≥ 1.1 mmol/l in women, and triglyceride (TG) ≥ 2.0 mmol/l),19 family history of CAD (first-degree relatives before the age of 55 in men and 65 years in women),20 hypertension [systolic blood pressure (BP) ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg and/or on antihypertensive treatment],21 and diabetes mellitus (DM) [symptoms of diabetes plus at least one of the following: plasma glucose concentration ≥ 11.1 mmol/l, fasting plasma glucose ≥ 7.0 mmol/l, and two-hour postprandial (2-HPP) ≥ 11.1 mmol/l].22 With regard to recording opium addiction rate, the participants were asked to disclose whether they have ever used any type of drug and still continue. Opium addiction was defined on the basis of the diagnostic and statistical manual of mental disorders-4th edition (DSM-IV) criteria for substance dependence as regularly consumption of inhalation or orally opium more than 3 times per week.23 Based on this definition, participants were classified into two groups: 1- current opium-addicted cases (n = 850) and 2- non-addicted cases. In current study and out of the defined KERCADRS study population, 217 men aged 40-70 years were randomly selected and prospectively underwent measurement of homocysteine. Those with malignant disease, severe renal insufficiency, cirrhosis, active liver disease attributable to viral infection, and/or other acute infectious or inflammatory disorders were all excluded. The study was approved by the research and Ethics Committees of the Kerman University of Medical Sciences and informed consent was obtained from all participants. BP was measured in sitting position after at least 10 minutes at rest using a Standard Mercury Manometer (Richter, Germany). If abnormal, BP was measured once again at the end of the session (at least 30 minutes after the first measurement) in the same conditions. For biochemical analysis, blood samples of 5 ml were drawn after 12 hours overnight fasting for measuring lipid profile, fasting blood sugar (FBS), and also homocysteine. Plasma glucose was measured using the glucose oxidase peroxidase method (KIMIA Kit, Code 890410, Iran). The level of serum lipid profile was also determined by standard enzymatic procedures (KIMIA Kit, Code 890201 for serum TG, and Code 890303 for total cholesterol, Iran). An enzyme immunoassay kit (Axis-Shield Diagnostics, UK) was used to measure homocysteine in serum samples. Elevated homocysteine level in men was considered > 15 μmol/l.24 The sample size was estimated by the power analysis and sample size (PASS) for Windows software (PASS, NCSS 2000). Based on the data on Masoomi et al. study,1 the groups size of 90 achieved 90% power to detect at least 3.0% increase in homocysteine level in the opium-addicted group, with a significance level (alpha) of 0.05. Allowing for a 10% dropout rate, the study required at least 100 participants per arm 1. Results were presented as mean ± standard deviation (SD) for quantitative variables and were summarized by absolute frequencies and percentages for categorical variables. Categorical variables were compared using chi-square test or Fisher’s exact test when more than 20% of cells with expected count of < 5 were observed. Quantitative variables were also compared using t-test. Correlation between homocysteine level and other parameters were examined using the Pearson’s correlation coefficient test. Multivariable linear regression analysis was used to determine the role of opium addiction for predicting homocysteine level adjustment for age and risk profiles. Statistical significance was determined as a P ≤ 0.050. All statistical analysis was performed using SPSS software (version 20, SPSS Inc., Chicago, IL, USA).

Results

Table 1 compares baseline characteristics between the opium-addicted and non-addicted subjects. Regarding measured BP, both systolic and diastolic BPs were significantly lower in the addicted group, while other parameters were similar across the two groups. With respect to the association between serum homocysteine levels, the level of this biomarker was significantly higher in the opium-addicted ones compared to non-addicted individuals (11.49 ± 7.45 vs. 8.02 ± 3.87 μmol/l) (P < 0.001). In this regard, 21.3% of the opium users and only 3.2% of the non-users had homocysteine concentration > 15 μmol/l (P < 0.001). On the other hand, individuals addicted to opiates exhibited significantly elevated odds of having homocysteine level higher than 15 [odds ratio (OR) = 8.244, 95% confidence interval (CI) = 3.117-21.806].
Table 1

Baseline characteristics and laboratory parameters in study population

CharacteristicsOpium-addicted group Non-addicted group P
(n = 103)(n = 114)
Age (year) (mean ± SD)43.26 ± 4.5342.39 ± 4.870.091
History of hypertension [n (%)]17 (16.5)21 (18.4)0.711
History of diabetes [n (%)]10 (6.0)12 (7.2)0.659
Systolic BP (mmHg) (mean ± SD)113.13 ± 14.68116.38 ± 15.410.047
Diastolic BP (mmHg) (mean ± SD)76.86 ± 10.0079.02 ± 9.750.045
FBS (mg/dl) (mean ± SD)101.85 ± 31.16101.74 ± 38.060.977
Serum total cholesterol (mg/dl) (mean ± SD)192.56 ± 41.84199.41 ± 43.640.143
Serum TG (mg/dl) (mean ± SD)173.93 ± 129.06178.79 ± 122.550.724
Serum homocysteine (mg/dl)11.49 ± 7.458.02 ± 3.87< 0.001

SD: Standard deviation; FBS: Fasting blood sugar; BP: Blood pressure; TG: Triglyceride

Among different laboratory parameters including FBS, systolic and diastolic BPs, and lipid profiles, homocysteine level had a significant linear correlation only with FBS (r = 0.173, P = 0.002) (Figure 1). Multivariable linear regression model (Table 2) showed that opium addiction could strongly predict elevated homocysteine level in the study individuals [beta = 3.524, standard error (SE) = 0.852] (P < 0.001).
Figure 1

Correlation between serum homocysteine level and FBS FBS: Fasting blood sugar

Table 2

Multivariable linear analysis for determining role of opium addiction for predicting elevation of plasma homocysteine level

ItemBetaSEP
Opium addiction-3.5240.852< 0.001
Age-0.1050.0920.253
History of hypertension-0.1001.1710.932
History of diabetes1.2741.6620.445
Systolic BP (mmHg)0.0140.0430.736
Diastolic BP (mmHg)-0.0360.0620.565
FBS (mg/dl)0.0320.0140.024
Serum total cholesterol (mg/dl)0.0150.0100.145

FBS: Fasting blood sugar; BP: blood pressure; SE: Standard error

Discussion

In some recent studies particularly on diabetics, it has been clearly determined an association between the elevation of plasma homocysteine levels and higher prevalence of some diabetes complications such as peripheral arteriopathy and nephropathy. Furthermore, it has been suggested that the elevated homocysteine can be associated with high levels of fibrinogen, lipoprotein (a), microalbuminuria, and BP levels.25 In some others, the association between serum homocysteine level and traditional CAD risk factors was only observed for systolic hypertension and there was no significant relationship between homocysteine level and other coronary risk profiles such as DM, hyperlipidemia, and smoking habit.26 We could show this relationship only for elevated blood sugar that the positive correlation was observed between homocysteine concentration and FBS. Recent studies have demonstrated that under diabetic conditions, the catabolism of homocysteine was enhanced by transcriptional regulation of hepatic cystathionine beta-synthase and these changes were prevented by treatment with insulin.27 In fact, plasma homocysteine levels are elevated in patients with diabetes, particularly in patients with type 2 diabetes as well as in individuals in prediabetes states who exhibit insulin resistance. The levels of homocysteine in such individuals are also influenced by their insulin concentrations, therapy with insulin, and medications such as metformin and glitazones that can either raise or lower homocysteine levels.28 Although we showed a relationship between FBS and homocysteine level, but this relationship was not detected between this marker and presence or absence of the history of DM. It seems that a considerable number of our population with diabetes had an irregular and uncontrolled blood sugar on the time of study. Therefore, it should be assessed this relationship in non-diabetic population or on all patients with diabetes with regular antidiabetic regimens. Based on our knowledge, this study was the first study that assessed changes in homocysteine level in opium addiction patients. In a study by Kulkarni et al., the effect of heavy alcohol consumption on serum malondialdehyde, homocysteine status, and glutathione-S-transferase activities in alcoholics consuming illicit liquor from the lower socioeconomic background.29 They showed an increase in serum homocysteine level in heavy alcohol drinkers and indicated that increasing homocysteine activities might enhance the susceptibility to vascular diseases in heavy illicit drinkers with poor nutritional status; however, it seems that the pathophysiological effects of opium use on concentration and activation of homocysteine might be different of alcohol use.29 It has been demonstrated that opiate addicts present lower levels in folic acid than the control group, but no significant differences were observed for vitamin B-12.30 This can explain the changes in level and homocysteine metabolism in opium users. Moreover, deleterious effects of opium consumption on homocysteine metabolism might be explained by its effects on nutritional status. Opium use can cause poor appetite and apathy regarding diet and nutrition. Opiate addicts and especially those with heavier consumption, develop anorexia which is determined by the poor consumption of food and drink leading to malnutrition.31 Morabia et al. have deduced that opiate addicts replace foods that are rich in fat and animal proteins with those that are rich in carbohydrates, especially sucrose and alcohol.32 It can result in an abnormality in homocysteine metabolism or its related enzymatic synthesis processes. Although the current evidence on this subject should be provided more and our obtained relationship between plasma homocysteine level and opium addiction especially with considering amount and root of consumption should be studied more.

Conclusion

The study indicated that opium consumption can be accompanied with the elevation of plasma homocysteine concentration.
  27 in total

1.  Homocysteine and its effects on in-stent restenosis.

Authors:  Giuseppe De Luca; Harry Suryapranata; Giovanni Gregorio; Helmut Lange; Massimo Chiariello
Journal:  Circulation       Date:  2005-11-08       Impact factor: 29.690

Review 2.  Homocysteine concentrations in patients with diabetes mellitus--relationship to microvascular and macrovascular disease.

Authors:  Alan N Elias; Steven Eng
Journal:  Diabetes Obes Metab       Date:  2005-03       Impact factor: 6.577

3.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

4.  Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease.

Authors:  S S Kang; P W Wong; H Y Cook; M Norusis; J V Messer
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

5.  Plasma homocyst(e)ine levels in men with premature coronary artery disease.

Authors:  J J Genest; J R McNamara; D N Salem; P W Wilson; E J Schaefer; M R Malinow
Journal:  J Am Coll Cardiol       Date:  1990-11       Impact factor: 24.094

6.  Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men.

Authors:  A von Eckardstein; M R Malinow; B Upson; J Heinrich; H Schulte; R Schönfeld; E Köhler; G Assmann
Journal:  Arterioscler Thromb       Date:  1994-03

7.  [Influence of serum homocysteine level on coronary atherosclerosis in Japanese].

Authors:  Yuichi Kobori; Nobuhiro Tanaka; Osamu Matsuoka; Masaru Aikawa; Naohisa Shindo; Hideyuki Kobayashi; Tomohiko Teramoto; Kenji Takazawa; Akira Yamashina; Nobuo Tanaka
Journal:  J Cardiol       Date:  2004-05       Impact factor: 3.159

Review 8.  Plasma homocyst(e)ine and arterial occlusive diseases: a mini-review.

Authors:  M R Malinow
Journal:  Clin Chem       Date:  1995-01       Impact factor: 8.327

Review 9.  Interrelationship between diabetes and homocysteine metabolism: hormonal regulation of cystathionine beta-synthase.

Authors:  Kevin L Schalinske
Journal:  Nutr Rev       Date:  2003-04       Impact factor: 7.110

10.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Authors:  C J Boushey; S A Beresford; G S Omenn; A G Motulsky
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

View more
  9 in total

1.  Prevalence of dyslipidemia and its association with opium consumption in the Rafsanjan cohort study.

Authors:  Zahra Jamali; Mojgan Noroozi Karimabad; Parvin Khalili; Tabandeh Sadeghi; Ahmadreza Sayadi; Faegheh Mohammadakbari Rostamabadi; Carlo La Vecchia; Ali Esmaeili-Nadimi
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

Review 2.  Epigenetic Regulation of Circadian Clocks and Its Involvement in Drug Addiction.

Authors:  Lamis Saad; Jean Zwiller; Andries Kalsbeek; Patrick Anglard
Journal:  Genes (Basel)       Date:  2021-08-19       Impact factor: 4.096

Review 3.  The Impact of Opium Consumption on Blood Glucose, Serum Lipids and Blood Pressure, and Related Mechanisms.

Authors:  Hamid Najafipour; Ahmad Beik
Journal:  Front Physiol       Date:  2016-10-13       Impact factor: 4.566

4.  B12 and Folate Concentrations in Opium Addicts Compared to Healthy Subjects: A Case Control Study from Kerman Coronary Artery Disease Risk Study.

Authors:  Ahmad Gholamhossenian; Beydolah Shahouzehi; Mostafa Shokoohi; Hamid Najafipour
Journal:  Addict Health       Date:  2018-07

5.  The effects of opium on the cardiovascular system: a review of side effects, uses, and potential mechanisms.

Authors:  Samaneh Nakhaee; Saeedeh Ghasemi; Kimiya Karimzadeh; Nasim Zamani; Samaneh Alinejad-Mofrad; Omid Mehrpour
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-04-17

Review 6.  Opium and cardiovascular health: A devil or an angel?

Authors:  Pegah Roayaei; Arya Aminorroaya; Ali Vasheghani-Farahani; Alireza Oraii; Saeed Sadeghian; Hamidreza Poorhosseini; Farzad Masoudkabir
Journal:  Indian Heart J       Date:  2020-10-20

7.  Effect of opium consumption on cardiovascular diseases - a cross- sectional study based on data of Rafsanjan cohort study.

Authors:  Parvin Khalili; Fatemeh Ayoobi; Maryam Mohamadi; Ahmad Jamalizadeh; Carlo La Vecchia; Ali Esmaeili-Nadimi
Journal:  BMC Cardiovasc Disord       Date:  2021-01-02       Impact factor: 2.298

8.  Association of Opium Addiction with Coronary Artery Ectasia and Coronary Artery Disease.

Authors:  Naemeh Bahrami; Gholamreza Asadikaram; Mohammad Masoumi
Journal:  Addict Health       Date:  2021-04

9.  Cross-sectional study of passive opiate smoking in relation to stroke and some of stroke attributable risk factors in women.

Authors:  Nazanin Jalali; Parvin Khalili; Saeed Bahrampour; Mohammad Mahmoudabadi; Ali Esmaeili Nadimi; Zahra Jalali
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.